SP3 and bacterial infectious disease: To determine if Eritoran (E5564) treatment of influenza virus-infected mice would affect susceptibility to 2° bacterial infection, mice were infected with PR8 on day 0, treated with vehicle or Eritoran on days 2 to 6, and then superinfected with Sp3 on day 7.